JP2000514405A - Dha―薬剤複合体 - Google Patents
Dha―薬剤複合体Info
- Publication number
- JP2000514405A JP2000514405A JP09542811A JP54281197A JP2000514405A JP 2000514405 A JP2000514405 A JP 2000514405A JP 09542811 A JP09542811 A JP 09542811A JP 54281197 A JP54281197 A JP 54281197A JP 2000514405 A JP2000514405 A JP 2000514405A
- Authority
- JP
- Japan
- Prior art keywords
- hydrochloride
- sodium
- acid
- tissue
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.非中枢神経系の状態を処置するために非中枢神経系組織に医薬の標的を定め る方法であって、そのような処置を必要とする対象に、シス−ドコサヘキサエン 酸とその状態の処置に有効な医薬との共有複合体を投与することからなる方法。 2.シス−ドコサヘキサエン酸を医薬と直接複合している、請求項1に記載の方 法。 3.組織が乳房組織であり、そして対象が医薬による乳房組織の処置を要する状 態にある、請求項2に記載の方法。 4.組織が胃腸器官組織であり、そして対象が医薬による胃腸器官組織の処置を 要する状態にある、請求項2に記載の方法。 5.組織が卵巣組織であり、そして対象が医薬による卵巣組織の処置を要する状 態にある、請求項2に記載の方法。 6.医薬が中枢神経系内で不活性である非中枢神経系活性剤である、請求項2に 記載の方法。 7.医薬が抗癌剤である、請求項2に記載の方法。 8.医薬がタキソールである、請求項7に記載の方法。 9.複合体が、 である、請求項8に記載の方法。 10.複合体が、 である、請求項8に記載の方法。 11.医薬がタキソテルである、請求項7に記載の方法。 12.複合体が、 である、請求項11に記載の方法。 13.複合体が、 である、請求項11に記載の方法。 14.複合体が、 である、請求項11に記載の方法。 15.複合体が、である、請求項11に記載の方法。 16.疾患が乳癌である、請求項1、2、3、6、7、8、9、10、11、1 2、13、14または15のいずれか一項に記載の方法。 17.疾患が結腸癌である、請求項1、2、3、6、7、8、9、10、11、 12、13、14または15のいずれか一項に記載の方法。 18.疾患が卵巣癌である、請求項1、2、3、6、7、8、9、10、11、 12、13、14または15のいずれか一項に記載の方法。 19.シス−ドコサヘキサエン酸と非中枢神経系活性剤との共有複合体、および 医薬上で許容される担体を含有する医薬製剤。 20.シス−ドコサヘキサエン酸が活性剤と直接複合している、請求項19に記 載の医薬製剤。 21.非中枢神経系活性剤が下記群から選択される組織に対して活性である、請 求項20に記載の医薬製剤: 血液および血液形成組織;心臓血管系組織;消化および排泄系組織;内分泌系組 織;筋肉系組織;再生系組織;呼吸器系組織;骨格系組織;および繊維および皮 膚系組織。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/651,312 | 1996-05-22 | ||
US08/651,312 US5795909A (en) | 1996-05-22 | 1996-05-22 | DHA-pharmaceutical agent conjugates of taxanes |
PCT/US1997/008867 WO1997044063A2 (en) | 1996-05-22 | 1997-05-22 | Dha-pharmaceutical agent conjugates |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2000514405A true JP2000514405A (ja) | 2000-10-31 |
JP2000514405A5 JP2000514405A5 (ja) | 2005-02-10 |
JP4402173B2 JP4402173B2 (ja) | 2010-01-20 |
Family
ID=24612392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54281197A Expired - Fee Related JP4402173B2 (ja) | 1996-05-22 | 1997-05-22 | Dha―薬剤複合体 |
Country Status (10)
Country | Link |
---|---|
US (3) | US5795909A (ja) |
EP (2) | EP0909183B1 (ja) |
JP (1) | JP4402173B2 (ja) |
AT (1) | ATE273025T1 (ja) |
AU (1) | AU725759B2 (ja) |
CA (1) | CA2255614C (ja) |
DE (1) | DE69730217T2 (ja) |
DK (1) | DK0909183T3 (ja) |
ES (1) | ES2222514T3 (ja) |
WO (1) | WO1997044063A2 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002512946A (ja) * | 1998-04-23 | 2002-05-08 | オリオン コーポレーション | レボシメンダンの制御放出経口用組成物 |
JP2002538224A (ja) * | 1999-03-09 | 2002-11-12 | プロタルガ,インコーポレーテッド | 脂肪酸−抗癌剤複合体およびこの使用 |
JP2005503423A (ja) * | 2001-09-27 | 2005-02-03 | ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド | コンジュゲートされた抗精神病薬およびこれらの使用 |
JP2007510648A (ja) * | 2003-10-30 | 2007-04-26 | ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク | タキソイド−脂肪酸コンジュゲート及びその医薬組成物 |
JP2013516486A (ja) * | 2010-01-08 | 2013-05-13 | カタバシス ファーマシューティカルズ,インコーポレイテッド | 脂肪酸フマル酸塩誘導体およびそれらの使用 |
Families Citing this family (248)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994392A (en) | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
US20030068362A1 (en) * | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
US20030073642A1 (en) * | 1993-02-22 | 2003-04-17 | American Bioscience, Inc. | Methods and formulations for delivery of pharmacologically active agents |
US20030133955A1 (en) * | 1993-02-22 | 2003-07-17 | American Bioscience, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US5972948A (en) * | 1994-07-01 | 1999-10-26 | Solvay Pharmaceuticals Gmbh | Method of inhibiting hyperglycemia and pharmaceutical composition for use therein |
US6231888B1 (en) | 1996-01-18 | 2001-05-15 | Perio Products Ltd. | Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps |
EP0914116B1 (en) * | 1996-05-22 | 2000-10-11 | Protarga Inc. | Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere |
US6576636B2 (en) * | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
KR100330373B1 (ko) * | 1996-05-28 | 2002-11-07 | 주식회사한국신약 | 탁솔을 함유한 주사용 약제 조성물 |
US6440980B1 (en) * | 1996-09-17 | 2002-08-27 | Avanir Pharmaceuticals | Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs |
GB2341390B (en) | 1997-05-21 | 2000-11-08 | Univ Leland Stanford Junior | Composition and method for enhancing transport across biological membranes |
US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
ZA986614B (en) * | 1997-07-25 | 1999-01-27 | Gilead Sciences | Nucleotide analog composition |
CA2302251A1 (en) | 1997-09-17 | 1999-03-25 | Eisai Co., Ltd. | Antimicrobial agent |
US20040136915A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing atropine |
US20030077228A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders |
US20050002867A1 (en) * | 1997-10-01 | 2005-01-06 | Novadel Pharma Inc. | Buccal, polar and non-polar sprays containing propofol |
US20030082107A1 (en) * | 1997-10-01 | 2003-05-01 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
US20050180923A1 (en) * | 1997-10-01 | 2005-08-18 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing testosterone |
EP2042161A1 (en) * | 1997-10-01 | 2009-04-01 | Novadel Pharma Inc. | Propellant-free spray composition comprising anti-emetic agent |
US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
US20050287075A1 (en) * | 1997-10-01 | 2005-12-29 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
US20030095927A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
US20040136913A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing sumatriptan |
US20090162300A1 (en) * | 1997-10-01 | 2009-06-25 | Dugger Iii Harry A | Buccal, polar and non-polar spray containing alprazolam |
US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
US20040141923A1 (en) * | 1997-10-01 | 2004-07-22 | Dugger Harry A. | Buccal, polar and non-polar spray containing alprazolam |
US20050281752A1 (en) * | 1997-10-01 | 2005-12-22 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
US20030095926A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
US20030190286A1 (en) * | 1997-10-01 | 2003-10-09 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma |
US20030185761A1 (en) * | 1997-10-01 | 2003-10-02 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
US20030095925A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
US20050163719A1 (en) * | 1997-10-01 | 2005-07-28 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing diazepam |
US20040136914A1 (en) | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing ondansetron |
US7632517B2 (en) * | 1997-10-01 | 2009-12-15 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing zolpidem |
US6153653A (en) * | 1997-11-26 | 2000-11-28 | Protarga, Inc. | Choline compositions and uses thereof |
US5977174A (en) * | 1997-11-26 | 1999-11-02 | Neuromedica, Inc. | Cholinergic compositions and uses thereof |
US6197764B1 (en) | 1997-11-26 | 2001-03-06 | Protarga, Inc. | Clozapine compositions and uses thereof |
US5955459A (en) * | 1997-11-26 | 1999-09-21 | Neuromedica, Inc. | Fatty acid-antipsychotic compositions and uses thereof |
WO1999036098A1 (fr) * | 1998-01-13 | 1999-07-22 | Suntory Limited | Composition antibacterienne contenant des antibiotiques et destinee a l'administration topique |
US6958148B1 (en) * | 1998-01-20 | 2005-10-25 | Pericor Science, Inc. | Linkage of agents to body tissue using microparticles and transglutaminase |
UA65607C2 (uk) | 1998-03-04 | 2004-04-15 | Орто-Макнейл Фармацевтикал, Інк. | Фармацевтична композиція (варіанти) та спосіб її приготування |
DK2263660T3 (en) | 1998-05-18 | 2018-01-02 | Takeda Pharmaceuticals Co | Orally disintegrating tablets. |
US7413759B2 (en) * | 1998-05-21 | 2008-08-19 | Beech-Nut Nutrition Corporation | Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions |
KR100634953B1 (ko) * | 1998-07-20 | 2006-10-17 | 스미스클라인 비참 코포레이션 | 에프로사르탄을 포함하는 생물학적으로 강화된 경구 고형투여 형태의 제제 |
CA2581111A1 (en) * | 1998-07-28 | 2000-02-10 | Takeda Pharmaceutical Company Limited | Rapidly disintegrable solid preparation |
KR100396171B1 (ko) * | 1998-08-10 | 2003-08-27 | 아사히 가세이 가부시키가이샤 | 염산 파수딜의 경구 서방성 제제 |
EP2266542A3 (en) * | 1998-10-01 | 2013-07-31 | Elan Pharma International Limited | Controlled release nanoparticulate compositions |
US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
US20080213378A1 (en) * | 1998-10-01 | 2008-09-04 | Elan Pharma International, Ltd. | Nanoparticulate statin formulations and novel statin combinations |
US20040013613A1 (en) * | 2001-05-18 | 2004-01-22 | Jain Rajeev A | Rapidly disintegrating solid oral dosage form |
US8236352B2 (en) | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
US6428814B1 (en) * | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
US6652864B1 (en) | 1998-12-21 | 2003-11-25 | Asilomar Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
US6787082B1 (en) * | 1999-01-29 | 2004-09-07 | Takeda Chemical Industries, Ltd. | Compressing mallet with coating treatment |
US7235583B1 (en) | 1999-03-09 | 2007-06-26 | Luitpold Pharmaceuticals, Inc., | Fatty acid-anticancer conjugates and uses thereof |
US6475984B2 (en) | 1999-04-29 | 2002-11-05 | The Nemours Foundation | Administration of leptin |
WO2000068229A2 (en) * | 1999-05-07 | 2000-11-16 | Wockhardt Limited | (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents |
US6197337B1 (en) * | 1999-05-10 | 2001-03-06 | Kenneth Weisman | Therapeutic uses of abarelix |
AU4834200A (en) * | 1999-05-10 | 2000-11-21 | Protarga, Inc. | Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof |
US7175855B1 (en) * | 1999-05-27 | 2007-02-13 | Pfizer Inc. | Ziprasidone suspension |
US20040115134A1 (en) * | 1999-06-22 | 2004-06-17 | Elan Pharma International Ltd. | Novel nifedipine compositions |
US6730293B1 (en) | 1999-08-24 | 2004-05-04 | Cellgate, Inc. | Compositions and methods for treating inflammatory diseases of the skin |
US6669951B2 (en) * | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US7229961B2 (en) | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
JP2003507438A (ja) | 1999-08-24 | 2003-02-25 | セルゲイト, インコーポレイテッド | オリゴアルギニン部分を使用する上皮組織を横切るおよび上皮組織内への薬物送達の増強 |
US6426367B1 (en) * | 1999-09-09 | 2002-07-30 | Efa Sciences Llc | Methods for selectively occluding blood supplies to neoplasias |
WO2001017524A1 (en) * | 1999-09-09 | 2001-03-15 | Efa Sciences Llc. | Methods for treating cell proliferative disorders including cancer |
US6380405B1 (en) | 1999-09-13 | 2002-04-30 | Nobex Corporation | Taxane prodrugs |
US6541508B2 (en) * | 1999-09-13 | 2003-04-01 | Nobex Corporation | Taxane prodrugs |
US6713454B1 (en) * | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
EP2289549A3 (en) | 1999-10-01 | 2011-06-15 | Immunogen, Inc. | Immunoconjugates for treating cancer |
US6383511B1 (en) * | 1999-10-25 | 2002-05-07 | Epicept Corporation | Local prevention or amelioration of pain from surgically closed wounds |
US20020045606A1 (en) * | 1999-12-02 | 2002-04-18 | Reddy Satyanarayana G. | Esters of vitamin D3 and uses thereof |
US6638906B1 (en) | 1999-12-13 | 2003-10-28 | Nobex Corporation | Amphiphilic polymers and polypeptide conjugates comprising same |
US6380253B1 (en) * | 2000-01-05 | 2002-04-30 | Efa Sciences Llc | Method of stabilizing and potentiating the action of anti-angiogenic substances |
AR035026A1 (es) | 2000-01-19 | 2004-04-14 | Baker Norton Pharma | Uso de pentosan polisulfato en el tratamiento de ciertas condiciones de la prostata |
US6649632B2 (en) | 2000-02-02 | 2003-11-18 | Fsu Research Foundation, Inc. | C10 ester substituted taxanes |
GEP20043323B (en) * | 2000-02-02 | 2004-02-10 | Univ Florida State Res Found | C10 Carbonate Substituted Taxanes as Antitumor Agents |
AR030188A1 (es) * | 2000-02-02 | 2003-08-13 | Univ Florida State Res Found | Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos |
US6730691B1 (en) | 2000-02-10 | 2004-05-04 | Miles A. Galin | Uses of alpha adrenergic blocking agents |
US6660750B2 (en) | 2000-02-15 | 2003-12-09 | University Of Iowa Research Foundation | Flavopiridol methods and compositions for HIV therapy |
US6452024B1 (en) | 2000-02-22 | 2002-09-17 | Chaichem Pharmaceuticals International | Process for extraction and purification of paclitaxel from natural sources |
US20030083342A1 (en) * | 2002-08-27 | 2003-05-01 | Steele Ronald Edward | Combination of organic compounds |
US20040156872A1 (en) * | 2000-05-18 | 2004-08-12 | Elan Pharma International Ltd. | Novel nimesulide compositions |
AU2002222931A1 (en) | 2000-07-19 | 2002-01-30 | University Of Pittsburgh | Synthesis and biological evaluation of analogs of the antimitotic marine natural product curacin a |
US7198795B2 (en) * | 2000-09-21 | 2007-04-03 | Elan Pharma International Ltd. | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions |
US6884777B1 (en) | 2000-11-14 | 2005-04-26 | The Nemours Foundation | Method for treating respiratory distress syndrome |
JP2005500988A (ja) * | 2001-03-23 | 2005-01-13 | ルイトポルド・ファーマシューティカルズ・インコーポレーテッド | 脂肪族アミン薬物複合体 |
EP1423107B1 (en) * | 2001-03-23 | 2012-05-09 | Luitpold Pharmaceuticals, Inc. | Fatty alcohol drug conjugates |
US20020198228A1 (en) * | 2001-04-03 | 2002-12-26 | Kaura Sita R. | Composition and method for the treatment of respiratory desease |
US20020198209A1 (en) * | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
WO2002089853A2 (en) * | 2001-05-03 | 2002-11-14 | Allergan, Inc. | Compositions having enhanced pharmacokinetic characteristics |
US7425565B2 (en) * | 2002-05-09 | 2008-09-16 | Cedars-Sinai Medical Center | Use of benzothiopenes to treat and prevent prostate cancer |
CA2354471A1 (en) * | 2001-07-31 | 2003-01-31 | Florida State University Research Foundation, Inc. | C10 ester substituted taxanes |
CA2354486A1 (en) * | 2001-07-31 | 2003-01-31 | Florida State University Research Foundation, Inc. | C7 ester substituted taxanes |
SG125889A1 (en) * | 2001-08-01 | 2006-10-30 | Univ Florida State Res Found | C7 ester subsituted taxanes |
SG129990A1 (en) * | 2001-08-01 | 2007-03-20 | Univ Florida State Res Found | C10 ester substituted taxanes |
US6852737B2 (en) * | 2001-08-06 | 2005-02-08 | Recordati Ireland Limited | Crude and crystalline forms of lercanidipine hydrochloride |
AU2004201240B2 (en) * | 2001-09-27 | 2008-08-07 | Bar Ilan University | Conjugated Psychotropic Drugs and Uses Thereof |
US7544681B2 (en) | 2001-09-27 | 2009-06-09 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
US6730667B2 (en) * | 2001-11-26 | 2004-05-04 | William R. Deagle | Iontophoresis disc pain blocker |
AU2002352982B2 (en) * | 2001-11-29 | 2008-03-06 | Sound Pharmaceuticals Incorporated | Methods and compositions for ameliorating the undesirable effects of chemotherapy |
AU2003202219B2 (en) * | 2002-01-04 | 2008-10-23 | Sound Pharmaceuticals Incorporated | Methods for treating hearing loss |
AU2003210517A1 (en) | 2002-02-04 | 2003-09-02 | Elan Pharma International, Ltd. | Drug nanoparticles with lysozyme surface stabiliser |
US20040101566A1 (en) * | 2002-02-04 | 2004-05-27 | Elan Pharma International Limited | Novel benzoyl peroxide compositions |
EP1487489A4 (en) * | 2002-03-04 | 2008-10-01 | Medimmune Inc | METHODS FOR PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN AVB3 ANTAGONIST ASSOCIATED WITH HMG-COA REDUCTASE INHIBITOR OR BISPHOSPHONATE |
WO2003094917A1 (fr) * | 2002-05-13 | 2003-11-20 | Takata Seiyaku Co., Ltd. | Composition medicinale contenant du vintoperol destinee a une administration transdermique |
US20040266776A1 (en) * | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
US20040002663A1 (en) * | 2002-06-26 | 2004-01-01 | Reeves William H. | Method and system for use in detecting a cancerous and precancerous pathology |
JP4776229B2 (ja) * | 2002-07-16 | 2011-09-21 | エラン ファーマ インターナショナル,リミティド | 安定なナノ粒子活性物質の液体投与組成物 |
US20040023935A1 (en) * | 2002-08-02 | 2004-02-05 | Dey, L.P. | Inhalation compositions, methods of use thereof, and process for preparation of same |
US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
WO2004033478A2 (en) * | 2002-10-08 | 2004-04-22 | Sepracor Inc. | Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory |
US20040109826A1 (en) * | 2002-12-06 | 2004-06-10 | Dey, L.P. | Stabilized albuterol compositions and method of preparation thereof |
EA200500804A1 (ru) * | 2002-12-10 | 2005-12-29 | Биосинексус Инкорпорейтед | Топические противоинфекционные композиции |
US7524515B2 (en) * | 2003-01-10 | 2009-04-28 | Mutual Pharmaceuticals, Inc. | Pharmaceutical safety dosage forms |
EP1583539A2 (en) * | 2003-01-13 | 2005-10-12 | Cedars-Sinai Medical Center | Paricalcitol as a chemotherapeutic agent |
US6759539B1 (en) | 2003-02-27 | 2004-07-06 | Chaichem Pharmaceuticals International | Process for isolation and purification of paclitaxel from natural sources |
US7811606B2 (en) * | 2003-04-16 | 2010-10-12 | Dey, L.P. | Nasal pharmaceutical formulations and methods of using the same |
US8912174B2 (en) * | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
US9808471B2 (en) * | 2003-04-16 | 2017-11-07 | Mylan Specialty Lp | Nasal pharmaceutical formulations and methods of using the same |
US8709998B2 (en) * | 2003-04-22 | 2014-04-29 | Ipsen Pharma S.A.S. | Peptide vectors |
US7429565B2 (en) | 2003-04-25 | 2008-09-30 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
CA2527024C (en) * | 2003-05-28 | 2012-08-21 | Paul Anziano | Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase |
GB2419529B (en) * | 2003-07-17 | 2008-01-09 | Cotherix Inc | Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome |
US20050113314A1 (en) * | 2003-08-29 | 2005-05-26 | Fong Benson M. | Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome |
US20060089374A1 (en) * | 2003-07-17 | 2006-04-27 | Glenn Cornett | Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease |
US20050187278A1 (en) * | 2003-08-28 | 2005-08-25 | Pharmacia Corporation | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors |
US20050148534A1 (en) * | 2003-09-22 | 2005-07-07 | Castellino Angelo J. | Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
GB0322994D0 (en) * | 2003-10-01 | 2003-11-05 | Novartis Ag | Organic compounds |
US20080045559A1 (en) * | 2003-10-29 | 2008-02-21 | Sonus Pharmaceuticals, Inc. | Tocopherol-modified therapeutic drug compounds |
CA2543722C (en) * | 2003-10-29 | 2011-01-04 | Sonus Pharmaceuticals, Inc. | Tocopherol-modified therapeutic drug compounds |
GB0326180D0 (en) * | 2003-11-11 | 2003-12-17 | Leuven K U Res & Dev | Biocompatible coating of medical devices |
SV2006002010A (es) | 2004-02-13 | 2006-08-23 | Univ Florida State Res Found | Taxanos sustituidos con esteres de ciclopentilo en c10 |
CN1960721A (zh) | 2004-03-05 | 2007-05-09 | 佛罗里达州立大学研究基金有限公司 | C7乳酰氧基取代的紫杉烷类 |
US20100009928A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and taxanes and methods of use thereof |
US20110008327A1 (en) * | 2004-03-29 | 2011-01-13 | Cheng Jin Q | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
US20100173864A1 (en) | 2004-03-29 | 2010-07-08 | Cheng Jin Q | Compositions including triciribine and one or more platinum compounds and methods of use thereof |
LT2574341T (lt) | 2004-03-29 | 2017-09-11 | University Of South Florida | Navikų ir vėžio efektyvus gydymas triciribino fosfatu |
US20100028339A1 (en) | 2004-03-29 | 2010-02-04 | Cheng Jin Q | Compositions including triciribine and trastuzumab and methods of use thereof |
US20100009929A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
GB0413730D0 (en) * | 2004-06-18 | 2004-07-21 | Tillotts Pharma Ag | A pharmaceutical composition and its use |
GB0413729D0 (en) * | 2004-06-18 | 2004-07-21 | Tillotts Pharma Ag | A pharmaceutical composition and its use |
JP2008508291A (ja) | 2004-07-27 | 2008-03-21 | ギリアード サイエンシーズ, インコーポレイテッド | 抗hiv剤としてのヌクレオシドホスホネート結合体 |
US20060154959A1 (en) * | 2005-01-13 | 2006-07-13 | Navitas Pharma | Combination therapies of cicletanine and carvedilol |
EP2813225B1 (en) * | 2004-09-24 | 2017-12-13 | University of Maryland, Baltimore | Method of treating organophosphorous poisoning |
US9132135B2 (en) * | 2004-09-24 | 2015-09-15 | University Of Maryland, Baltimore | Method of treating organophosphorous poisoning |
EP1827450A4 (en) * | 2004-11-17 | 2009-04-22 | Cypress Bioscience Inc | METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE |
US20080096915A1 (en) * | 2005-01-13 | 2008-04-24 | Greenberg Traurig LLP | Compositions for the treatment of metabolic disorders |
US20070141174A1 (en) * | 2005-01-13 | 2007-06-21 | Navitas Pharma, Inc. | Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension |
US7989499B2 (en) * | 2005-02-09 | 2011-08-02 | Mitotek, Llc | Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase |
WO2006096759A2 (en) * | 2005-03-08 | 2006-09-14 | Sound Pharmaceuticals Incorporated | Methods and compositions for treating cancer |
US20060216767A1 (en) * | 2005-03-22 | 2006-09-28 | Saladax Biomedical Inc. | Docetaxel immunoassay |
BRPI0611159A2 (pt) | 2005-05-04 | 2012-07-31 | Pronova Biopharma Norge As | composto e respectivo processo e fabrico, composiÇÕes farmacÊutica e de Ácido graxo, usos de composto e mÉtodos de controle da reduÇço do peso corpàreo e/ou prevenÇço do ganho de peso corpàreo, de tratamento e/ou prevenÇço da obesidade ou de uma condiÇço de sobrepeso, do diabete, de doenÇas relacionadas com a amiloidose, de tratamento ou profilaxia de fatores méltiplos de risco para doenÇas cardiovasculares e de prevenÇço do derrame cerebral, de ataques isquÊmicos cerebrais ou passageiros relacionados com a aterosclerose de vÁrias artÉrias |
EP1888120B1 (en) * | 2005-06-07 | 2012-12-05 | Ramot at Tel Aviv University Ltd. | Novel salts of conjugated psychotropic drugs and processes of preparing same |
US20070105817A1 (en) * | 2005-11-09 | 2007-05-10 | Jim Page | Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension |
CN1870631B (zh) * | 2005-11-11 | 2010-04-14 | 华为技术有限公司 | 媒体网关的门控方法 |
US20090156562A1 (en) * | 2005-11-14 | 2009-06-18 | Winch Peter D | Novel colored solutions of injectable drugs and their pharmaceutically acceptable salts |
US8722884B2 (en) * | 2005-12-01 | 2014-05-13 | Verastem, Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
WO2007070514A1 (en) | 2005-12-13 | 2007-06-21 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
CZ300305B6 (cs) * | 2005-12-20 | 2009-04-15 | Heaton, A. S. | Farmaceutická kompozice obsahující derivát taxanu se zlepšenou terapeutickou úcinností |
AU2007237874A1 (en) * | 2006-04-13 | 2007-10-25 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
WO2007123955A2 (en) * | 2006-04-19 | 2007-11-01 | Novadel Pharma Inc. | Stable hydroalcoholic oral spray formulations and methods |
PL2020996T3 (pl) * | 2006-05-16 | 2012-04-30 | Gilead Sciences Inc | Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego |
FR2902659A1 (fr) | 2006-06-23 | 2007-12-28 | Pierre Fabre Medicament Sa | Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires |
MX2009000641A (es) | 2006-07-17 | 2009-02-12 | Univ Ramot | Conjugados que comprenden un farmaco sicotropico o un agonista de gaba y un acido organico y su uso en el tratamiento del dolor y otros desordenes del cns. |
US20080248135A1 (en) * | 2006-07-28 | 2008-10-09 | Collegium Pharmaceutical, Inc. | Combination Therapy for Otitis with Antiseptic and pH Adjustment |
WO2008021242A2 (en) * | 2006-08-10 | 2008-02-21 | The Research Foundation Of State University Of New York | Fluorotaxoid-fatty acid conjugates and pharmaceutical compositions thereof |
US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
CN101535238A (zh) | 2006-11-01 | 2009-09-16 | 普罗诺瓦生物医药挪威公司 | 作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质 |
DE602007013294D1 (de) * | 2006-12-21 | 2011-04-28 | Pfizer Prod Inc | Succinatsalz von 2-((4-(1-methyl-4(pyridin-4-yl)-1h-pyrazol-3-yl)phenoxy)methyl)chinolin |
WO2008079295A1 (en) * | 2006-12-22 | 2008-07-03 | Novadel Pharma Inc. | Stable anti-nausea oral spray formulations and methods |
AU2008203901A1 (en) * | 2007-01-03 | 2008-07-17 | Glenn V. Cornett | Cicletanine and PKC inhibitors in the treatment of pulmonary and cardiac disorders |
TWI384986B (zh) * | 2007-01-17 | 2013-02-11 | Lg Life Sciences Ltd | 抗病毒劑之順丁烯二酸單鹽以及含有該單鹽之醫藥組成物 |
AU2008226645B2 (en) * | 2007-03-09 | 2012-09-20 | Novartis Ag | Salts of 3- (1H-ind0l-3-yl) -4- [2- (4-methyl-piperazin-i-yl) -quinazolin-4-yl] -pyrrole-2, 5-di one |
US9220837B2 (en) * | 2007-03-19 | 2015-12-29 | Insuline Medical Ltd. | Method and device for drug delivery |
MX2009012109A (es) * | 2007-05-10 | 2010-02-22 | Novadel Pharma Inc | Composiciones contra el insomnio y metodos. |
US20090099062A1 (en) * | 2007-05-31 | 2009-04-16 | Ethan Lee | Pyrvinium For The Treatment of Cancer |
RS58449B1 (sr) | 2007-06-13 | 2019-04-30 | Incyte Holdings Corp | Upotreba soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h- pirazol-1-il)-3-ciklopentilpropionitrila |
US8067632B2 (en) | 2007-07-26 | 2011-11-29 | The Board Of Trustees Of The Leland Stanford Junior University | Process to produce prostratin and structural or functional analogs thereof |
JP2010540555A (ja) * | 2007-09-26 | 2010-12-24 | マウント シナイ スクール オブ メディシン | アザシチジン類似体およびその使用 |
US7985325B2 (en) * | 2007-10-30 | 2011-07-26 | Novellus Systems, Inc. | Closed contact electroplating cup assembly |
CN101328159B (zh) * | 2007-11-05 | 2011-12-21 | 孙汉翔 | 紫杉烷前体抗癌药及其药物组合物和用途 |
CA2709219A1 (en) * | 2007-12-12 | 2009-06-18 | Ultimorphix Technologies B.V. | Solid forms of tenofovir disoproxil |
PE20091156A1 (es) * | 2007-12-17 | 2009-09-03 | Astrazeneca Ab | Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo |
WO2009101616A1 (en) | 2008-02-11 | 2009-08-20 | Ramot At Tel Aviv University Ltd. | Novel conjugates for treating neurodegenerative diseases and disorders |
WO2009145981A1 (en) | 2008-03-31 | 2009-12-03 | Florida State University Research Foundation, Inc. | C(10) ethyl ester and c(10) cyclopropyl ester substituted taxanes |
MX2010011165A (es) * | 2008-04-10 | 2011-02-22 | Abraxis Bioscience Llc | Composiciones de derivados de taxano hidrofobos y sus usos. |
MX2010012442A (es) * | 2008-05-13 | 2011-10-11 | Astrazeneca Ab | Sal de fumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-m etilcarbamoilmetil) piperidin-4-il]oxi}quinazolina. |
US8835506B2 (en) | 2008-06-05 | 2014-09-16 | Stc.Unm | Methods and related compositions for the treatment of cancer |
NZ601932A (en) | 2008-07-08 | 2014-03-28 | Catabasis Pharmaceuticals Inc | Fatty acid acetylated salicylates and their uses |
US9085527B2 (en) | 2008-07-08 | 2015-07-21 | Catabasis Pharmaceuticals, Inc. | Fatty acid acylated salicylates and their uses |
WO2010005986A1 (en) | 2008-07-08 | 2010-01-14 | Gilead Sciences, Inc. | Salts of hiv inhibitor compounds |
US9145396B2 (en) | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
US8604191B2 (en) * | 2008-12-01 | 2013-12-10 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3YLVINYL)pyrimidine |
AU2009324495B2 (en) * | 2008-12-11 | 2015-12-24 | Biovista, Inc. | Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles |
MY152669A (en) * | 2008-12-18 | 2014-10-31 | Novartis Ag | Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid |
US9034389B2 (en) | 2009-03-11 | 2015-05-19 | Stable Solutions Llc | Omega-3 enriched fish oil-in-water parenteral nutrition emulsions |
US8993625B2 (en) * | 2009-03-11 | 2015-03-31 | Stable Solutions Llc | Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle |
CN102458112A (zh) * | 2009-04-10 | 2012-05-16 | 阿布拉科斯生物科学有限公司 | 纳米颗粒制剂及其用途 |
RU2636614C2 (ru) * | 2009-05-19 | 2017-11-24 | Вивия Байотек С.Л. | Способы персонализированного медицинского тестирования ex vivo на гематологические новообразования |
EP3643312A1 (en) | 2009-05-22 | 2020-04-29 | Incyte Holdings Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
AR078012A1 (es) * | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
AU2010329440A1 (en) | 2009-12-09 | 2012-08-09 | Bar-Ilan University | Methods of improving cognitive functions |
CN102985417B (zh) | 2010-03-10 | 2015-01-28 | 因塞特公司 | 作为jak1抑制剂的哌啶-4-基氮杂环丁烷衍生物 |
EA035981B1 (ru) | 2010-05-21 | 2020-09-09 | Инсайт Холдингс Корпорейшн | Композиция ингибитора jak для местного применения |
WO2012038963A1 (en) | 2010-09-22 | 2012-03-29 | Ramot At Tel-Aviv University Ltd. | An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same |
EP2640725B1 (en) | 2010-11-19 | 2015-01-07 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
TW201249845A (en) | 2010-11-19 | 2012-12-16 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
US20120178813A1 (en) | 2011-01-12 | 2012-07-12 | Thetis Pharmaceuticals Llc | Lipid-lowering antidiabetic agent |
WO2012154554A1 (en) * | 2011-05-06 | 2012-11-15 | Catabasis Pharmaceuticals, Inc. | Fatty acid triterpene derivatives and their uses |
WO2012177606A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
CN102952138B (zh) * | 2011-08-17 | 2016-07-06 | 上海特化医药科技有限公司 | 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用 |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
PE20141198A1 (es) | 2011-09-19 | 2014-10-05 | Orexo Ab | Nueva composicion farmaceutica resistente al abuso para el tratamiento de la dependencia de opioides |
EP2847158A4 (en) * | 2012-05-07 | 2015-12-30 | Cellix Bio Private Ltd | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS AND NEURODEGENERATIVE DISORDERS |
TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
US8765811B2 (en) | 2012-07-10 | 2014-07-01 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
US9382187B2 (en) | 2012-07-10 | 2016-07-05 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
CN113384545A (zh) | 2012-11-15 | 2021-09-14 | 因赛特公司 | 鲁索利替尼的缓释剂型 |
SI3489239T1 (sl) | 2013-03-06 | 2022-04-29 | Incyte Holdings Corporation | Postopki in intermediati za pripravo zaviralca JAK |
EA201690357A1 (ru) | 2013-08-07 | 2016-07-29 | Инсайт Корпорейшн | Лекарственные формы с замедленным высвобождением для ингибитора jak1 |
US10463684B2 (en) | 2014-01-29 | 2019-11-05 | Board Of Regents, The Uneversety Of Texas System | Nucleobase analogue derivatives and their applications |
US9505709B2 (en) | 2014-05-05 | 2016-11-29 | Thetis Pharmaceuticals Llc | Compositions and methods relating to ionic salts of peptides |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
AU2015277509A1 (en) | 2014-06-18 | 2017-01-05 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of active agents |
US9242008B2 (en) | 2014-06-18 | 2016-01-26 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of fatty acids |
CN104225615B (zh) * | 2014-09-24 | 2017-02-01 | 东南大学 | 一种紫杉醇类磷脂化合物、其药物组合物及应用 |
WO2016198971A1 (en) * | 2015-06-08 | 2016-12-15 | Mohan M Alapati | Compositions and methods for the treatment of hyperglycemia and metabolic syndrome |
CA3017367A1 (en) * | 2016-03-15 | 2017-09-21 | Vitality Biopharma, Inc. | Methods and compositions for the treatment of demyelinating disorders |
CN109562186B (zh) | 2016-06-03 | 2022-09-13 | 西蒂斯制药有限责任公司 | 与专门促消退介质的盐有关的组合物和方法 |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
WO2019027920A1 (en) | 2017-08-01 | 2019-02-07 | Gilead Sciences, Inc. | CRYSTALLINE FORMS OF ETHYL ((S) - (((((2R, 5R) -5- (6-AMINO-9H-PURIN-9-YL) -4-FLUORO-2,5-DIHYDROFURAN-2-YL) OXY ) METHYL) (PHENOXY) PHOSPHORYL) -L-ALANINATE (GS-9131) FOR THE TREATMENT OF VIRAL INFECTIONS |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
SI3746429T1 (sl) | 2018-01-30 | 2023-01-31 | Incyte Corporation | Postopki za pripravo (1-(3-fluoro-2-(trifluorometil)izonikotinil) piperidin-4-ona) |
WO2019191684A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
US10822346B2 (en) * | 2018-04-17 | 2020-11-03 | Cardurion Pharmaceuticals, Llc | Meglumine salts of thienopyrimidines |
CA3105879A1 (en) | 2018-07-18 | 2020-01-23 | Manzanita Pharmaceuticals, Inc. | Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof |
US11643438B2 (en) | 2018-07-20 | 2023-05-09 | The Board Of Regents Of The University Of Oklahoma | Antimicrobial peptides and methods of use |
CA3103995A1 (en) | 2018-07-26 | 2020-01-30 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
WO2020191477A1 (en) * | 2019-03-22 | 2020-10-01 | Integrated Nanotherapeutics Inc. | Lipid conjugate prepared from scaffold moiety |
EP4061367A1 (en) | 2019-11-22 | 2022-09-28 | Incyte Corporation | Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (142)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US449A (en) * | 1837-11-11 | Improvement in the mode of preparing paint for the protection of buildings against fire | ||
US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
US3621048A (en) * | 1968-03-14 | 1971-11-16 | Colgate Palmolive Co | Quaternary ammonium compounds |
US4218234A (en) * | 1972-12-07 | 1980-08-19 | Novex Rt. | Soil conditioners |
SU477159A1 (ru) | 1973-07-27 | 1975-07-15 | Всесоюзный научно-исследовательский институт фитопатологии | Способ получени амидофосфорилоксиэтиламидов карбоновых кислот |
JPS5186479A (en) | 1975-01-22 | 1976-07-29 | Asahi Chemical Ind | 55 furuororashirujudotainoseizohoho |
DE2602175B2 (de) | 1975-01-22 | 1978-05-03 | Asahi Kasei Kogyo K.K., Osaka (Japan) | 1 -Alkanoyl-5-fluor-uracilderivate und ihre Verwendung |
US4097597A (en) * | 1977-02-23 | 1978-06-27 | Abbott Laboratories | Dibenzo b,e! 1,4!diazepines |
US4351831A (en) * | 1977-11-02 | 1982-09-28 | Massachusetts Institute Of Technology | Process and composition for treating disorders by administering isoxsurpine and choline |
US4287184A (en) | 1977-11-23 | 1981-09-01 | The Massachusetts General Hospital | Process for healing wounds |
US4185095A (en) | 1977-11-23 | 1980-01-22 | The Massachusetts General Hospital | Nerve growth factor |
US4407744A (en) | 1977-11-23 | 1983-10-04 | Young David M | Process for obtaining nerve growth factor |
JPS5553208A (en) | 1978-10-13 | 1980-04-18 | Mitsubishi Chem Ind Ltd | Insecticide |
IT7927748A0 (it) * | 1979-11-30 | 1979-11-30 | Simes | Derivati dell'acido 6,6'-diapopsi psicarotenedioico e relativi procedimenti di preparazione. |
US4346085A (en) * | 1980-02-29 | 1982-08-24 | Massachusetts Institute Of Technology | Process and composition for treating disorders by administering amphetamine and choline |
US4636494A (en) * | 1981-01-30 | 1987-01-13 | Massachusetts Institute Of Technology | Process and composition for treating disorders by administering amphetamine and choline |
JPS58177953A (ja) * | 1982-04-13 | 1983-10-18 | Eisai Co Ltd | ポリプレニルカルボン酸アミドおよびその製造方法 |
JPS5925327A (ja) | 1982-07-31 | 1984-02-09 | Hidematsu Hirai | 抗腫瘍性複合体の製造方法 |
US4558049A (en) | 1982-11-24 | 1985-12-10 | Farmitalia Carlo Erba S.P.A. | Antipsycotic benzoxazines |
US5169762A (en) | 1983-03-03 | 1992-12-08 | Genentech, Inc. | Human nerve growth factor by recombinant technology |
JPS59204175A (ja) | 1983-04-28 | 1984-11-19 | Terumo Corp | 5―フルオロウラシル誘導体を有効成分とする血小板凝集抑制剤 |
US4704393A (en) * | 1983-10-20 | 1987-11-03 | Terumo Kabushiki Kaisha | 1-substituted 5-fluorouracil useful for inhibiting the aggregation of platelets |
US4550109A (en) * | 1984-05-31 | 1985-10-29 | The Board Of Regents, The University Of Texas System | Lipoidal biopterin compounds |
US4684646A (en) * | 1984-06-26 | 1987-08-04 | Merck & Co., Inc. | 2-acylaminomethyl-1,4-benzodiazepine derivatives as CCK-antagonists |
US4868161A (en) * | 1984-06-29 | 1989-09-19 | City Of Hope | Method for promoting nerve regeneration |
IL72684A (en) | 1984-08-14 | 1989-02-28 | Israel State | Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs |
US4554272A (en) * | 1985-01-25 | 1985-11-19 | Merck & Co., Inc. | Substituted quinazolino-1,4-benzodiazepin-6,9-diones and their preparation |
US6448392B1 (en) * | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
US5223263A (en) * | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
US4729989A (en) | 1985-06-28 | 1988-03-08 | Merck & Co., Inc. | Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts |
US4692441A (en) | 1985-08-16 | 1987-09-08 | Merck & Co., Inc. | Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities |
US5246726A (en) | 1986-03-21 | 1993-09-21 | Efamol Ltd. | Iron-containing composition and method for treatment of cancer |
FR2601675B1 (fr) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
FR2601676B1 (fr) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Procede de preparation du taxol et du desacetyl-10 taxol |
US4902505A (en) * | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4968672A (en) | 1987-01-02 | 1990-11-06 | The United States Of America As Represented By The Department Of Health And Human Services | Adenosine receptor prodrugs |
US5459256A (en) | 1987-04-17 | 1995-10-17 | The Government Of The United States Of America As Represented By The Department Of Health And Human Services | Lipophilic, aminohydrolase-activated prodrugs |
SE8703625D0 (sv) | 1987-09-18 | 1987-09-18 | Kabivitrum Ab | New medical use |
JPH03501253A (ja) | 1987-09-22 | 1991-03-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | エイズ(aids)治療を目的とするリポソームによるヌクレオシド類似物質 |
US4943579A (en) | 1987-10-06 | 1990-07-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble prodrugs of camptothecin |
US5420276A (en) | 1987-11-03 | 1995-05-30 | Abbott Laboratories | Analogs of oxetanyl purines and pyrimidines |
JPH01153629A (ja) | 1987-12-11 | 1989-06-15 | Nippon Oil & Fats Co Ltd | 制癌剤 |
JPH01203331A (ja) | 1988-02-05 | 1989-08-16 | Rikagaku Kenkyusho | 制癌剤 |
US4939174A (en) * | 1988-02-26 | 1990-07-03 | Shashoua Victor E | Appetite suppression with dopamine-fatty acid conjugates |
US4933324A (en) * | 1988-02-26 | 1990-06-12 | Shashoua Victor E | Fatty acid-neuroactive drug conjugate as a prodrug |
US6107499A (en) * | 1988-02-26 | 2000-08-22 | Neuromedica, Inc. | Dopamine analog amide |
US5994392A (en) | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
US5284876A (en) | 1988-02-26 | 1994-02-08 | Neuromedica, Inc. | Method of treating tardive dyskinesia using dopaminergic agents of prodrugs of therapeutic agents |
JPH01287022A (ja) | 1988-05-12 | 1989-11-17 | Nippon Oil & Fats Co Ltd | 抗癌剤耐性克服剤 |
GB8813766D0 (en) | 1988-06-10 | 1988-07-13 | Efamol Holdings | Essential fatty acid compositions |
US6252060B1 (en) | 1988-07-07 | 2001-06-26 | Nexstar Pharmaceuticals, Inc. | Antiviral liponucleosides: treatment of hepatitis B |
JP2612619B2 (ja) | 1988-12-14 | 1997-05-21 | 財団法人相模中央化学研究所 | 含リン化合物よりなる経皮吸収促進剤 |
CH676909A5 (ja) | 1988-12-23 | 1991-03-28 | Nestle Sa | |
HU207287B (en) | 1989-01-17 | 1993-03-29 | Biosignal Kutato Fejlesztoe Kf | Polyene fatty acid derivatives of tyrozine-quinaze inhibiting activity and pharmaceutical composition containing them as active component |
IE980216A1 (en) | 1989-04-17 | 2000-02-23 | Scotia Holdings Plc | Anti-virals |
US5411947A (en) * | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
US5194654A (en) * | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
GB8918294D0 (en) | 1989-08-10 | 1989-09-20 | Efamol Holdings | Pharmaceutical compositions |
JPH03236315A (ja) | 1989-12-05 | 1991-10-22 | Nippon Oil & Fats Co Ltd | 抗精神病薬 |
GB9001121D0 (en) | 1990-01-18 | 1990-03-21 | Efamol Holdings | Efa compositions and therapy |
US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
US5545719A (en) * | 1990-05-01 | 1996-08-13 | Neuromedica, Inc. | Nerve growth peptides |
JP2800953B2 (ja) * | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
US5169764A (en) | 1990-08-08 | 1992-12-08 | Regeneron Pharmaceuticals, Inc. | Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras |
JP3139777B2 (ja) | 1990-08-27 | 2001-03-05 | フマキラー株式会社 | 組換えダニアレルゲン |
US5278324A (en) * | 1990-08-28 | 1994-01-11 | Virginia Tech Intellectual Properties, Inc. | Water soluble derivatives of taxol |
US5059699A (en) * | 1990-08-28 | 1991-10-22 | Virginia Tech Intellectual Properties, Inc. | Water soluble derivatives of taxol |
US5827819A (en) | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
MX9102128A (es) * | 1990-11-23 | 1992-07-08 | Rhone Poulenc Rorer Sa | Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene |
GB9108056D0 (en) | 1991-04-16 | 1991-06-05 | Hale Geoffrey | Synthetic antigen |
WO1992020362A1 (en) * | 1991-05-14 | 1992-11-26 | Shashoua Victor E | Nerve growth peptides and uses therefor |
US5369191A (en) * | 1992-01-23 | 1994-11-29 | Kureha Kagaku Kogyo K.K. | Aromatic thioether ketone/thioether sulfone copolymer and production process thereof |
IT1254515B (it) * | 1992-03-06 | 1995-09-25 | Indena Spa | Tassani di interesse oncologico, loro metodo di preparazione ed uso |
IT1254517B (it) * | 1992-03-06 | 1995-09-25 | Indena Spa | 14-beta idrossi-10-deacetil-baccatina iii, suoi derivati, loro prepazione ed impiego terapeutico |
US5214062A (en) | 1992-04-08 | 1993-05-25 | Clintec Nutrition Co. | Method and composition for treating immune disorders, inflammation and chronic infections |
GB9213077D0 (en) * | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
JPH0616548A (ja) | 1992-06-30 | 1994-01-25 | Sagami Chem Res Center | 組織異常増殖抑制剤 |
US5308832A (en) | 1992-07-27 | 1994-05-03 | Abbott Laboratories | Nutritional product for persons having a neurological injury |
DE4224737A1 (de) | 1992-07-27 | 1994-02-03 | Herbert Prof Dr Schott | Neue Cytosinnucleosidanaloga, Verfahren zu ihrer Herstellung und ihre Verwendung |
US5352596A (en) | 1992-09-11 | 1994-10-04 | The United States Of America As Represented By The Secretary Of Agriculture | Pseudorabies virus deletion mutants involving the EPO and LLT genes |
FR2696461B1 (fr) * | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent. |
US5453521A (en) * | 1992-10-05 | 1995-09-26 | Rhone-Poulenc Rorer S.A. | Process for obtaining 10-deacetylbaccatin III |
US5356928A (en) * | 1992-11-06 | 1994-10-18 | Hauser Chemical Research, Inc. | Cytotoxic agents |
FR2697841B1 (fr) * | 1992-11-12 | 1995-01-13 | Rhone Poulenc Rorer Sa | Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent. |
FR2698269B1 (fr) | 1992-11-24 | 1995-01-06 | Inst Nat Sante Rech Med | Nouveaux médicaments à base d'acides gras insaturés, utilisables notamment comme antiagrégants plaquettaires et/ou comme transporteurs privilégiés vers le cerveau. |
GB9224809D0 (en) | 1992-11-26 | 1993-01-13 | Scotia Holdings Plc | Schizophrenia |
CA2150470A1 (en) * | 1992-11-30 | 1994-06-09 | S.P.I. Synthetic Peptides Incorporated | Polyunsaturated fatty acyl-peptide composition |
FR2698871B1 (fr) * | 1992-12-09 | 1995-02-24 | Rhone Poulenc Rorer Sa | Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent. |
US5496714A (en) | 1992-12-09 | 1996-03-05 | New England Biolabs, Inc. | Modification of protein by use of a controllable interveining protein sequence |
GB9300125D0 (en) | 1993-01-06 | 1993-03-03 | Scotia Holdings Plc | Compositions containing esters of unsaturated fatty acids |
GB9301629D0 (en) | 1993-01-27 | 1993-03-17 | Scotia Holdings Plc | Formulations containing unsaturated fatty acids |
GB9304746D0 (en) | 1993-03-09 | 1993-04-28 | Scotia Holdings Plc | Treatment of viral infections |
IL105244A (en) | 1993-03-31 | 2003-07-31 | Dpharm Ltd | Prodrugs with enhanced penetration into cells |
US6413949B1 (en) | 1995-06-07 | 2002-07-02 | D-Pharm, Ltd. | Prodrugs with enhanced penetration into cells |
US5643909A (en) * | 1993-04-19 | 1997-07-01 | Syntex (U.S.A.) Inc. | 10,11-Methanodibenzosuberane derivatives |
US5336684A (en) * | 1993-04-26 | 1994-08-09 | Hauser Chemical Research, Inc. | Oxidation products of cephalomannine |
FR2707293A1 (fr) * | 1993-07-08 | 1995-01-13 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur préparation et les compositions pharmaceutiques qui les contiennent. |
US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
TW406020B (en) | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
US5824701A (en) * | 1993-10-20 | 1998-10-20 | Enzon, Inc. | Taxane-based prodrugs |
FR2712288B1 (fr) * | 1993-11-08 | 1996-01-05 | Rhone Poulenc Rorer Sa | Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent. |
FR2712289B1 (fr) * | 1993-11-08 | 1996-01-05 | Rhone Poulenc Rorer Sa | Nouveaux dérivés de taxicine, leur préparation et les compositions pharmaceutiques qui les contiennent. |
US5480799A (en) | 1993-12-10 | 1996-01-02 | The University Of North Carolina At Chapel Hill | Sperm antigen corresponding to a sperm zona binding protein autoantigenic epitope |
IT1264987B1 (it) | 1993-12-14 | 1996-10-17 | Prospa Bv | Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono |
US5447936A (en) * | 1993-12-22 | 1995-09-05 | Bionumerik Pharmaceuticals, Inc. | Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof |
GB9403857D0 (en) * | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
US5925669A (en) * | 1994-03-22 | 1999-07-20 | Molecular/Structural Bio Technologies, Inc. | Carrier compositions for anti-neoplastic drugs |
US5468754A (en) * | 1994-04-19 | 1995-11-21 | Bionumerik Pharmaceuticals, Inc. | 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof |
US5604198A (en) * | 1994-05-12 | 1997-02-18 | Poduslo; Joseph F. | Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents |
US5534499A (en) * | 1994-05-19 | 1996-07-09 | The University Of British Columbia | Lipophilic drug derivatives for use in liposomes |
FR2721023B1 (fr) * | 1994-06-09 | 1996-07-12 | Rhone Poulenc Rorer Sa | Nouveaux Taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent. |
JPH0815133A (ja) | 1994-06-29 | 1996-01-19 | Hitachi Ltd | 分析素子 |
FR2721928A1 (fr) * | 1994-07-04 | 1996-01-05 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
US5597719A (en) | 1994-07-14 | 1997-01-28 | Onyx Pharmaceuticals, Inc. | Interaction of RAF-1 and 14-3-3 proteins |
JPH0827010A (ja) | 1994-07-19 | 1996-01-30 | Nichinichi Seiyaku Kk | 制癌免疫療法剤 |
WO1996004001A1 (en) * | 1994-08-05 | 1996-02-15 | Molecular/Structural Biotechnologies, Inc. | Site-specific biomolecular complexes |
US5716614A (en) | 1994-08-05 | 1998-02-10 | Molecular/Structural Biotechnologies, Inc. | Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier |
JPH08163991A (ja) | 1994-12-15 | 1996-06-25 | Mitsui Petrochem Ind Ltd | タキサン型ジテルペンの製造方法 |
US5580899A (en) * | 1995-01-09 | 1996-12-03 | The Liposome Company, Inc. | Hydrophobic taxane derivatives |
EP0804459A4 (en) | 1995-01-16 | 1999-05-26 | Commw Scient Ind Res Org | CONJUGATES THERAPEUTIC COMPOUND - FATTY ACID |
US5977061A (en) | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
MY118354A (en) * | 1995-05-01 | 2004-10-30 | Scarista Ltd | 1,3-propane diol derivatives as bioactive compounds |
US5532374A (en) * | 1995-06-06 | 1996-07-02 | Hitachi Chemical Company, Ltd. | Method of preparation of bis-quinolines |
JPH0925231A (ja) | 1995-07-13 | 1997-01-28 | Sagami Chem Res Center | 癌転移抑制剤 |
JPH0930963A (ja) | 1995-07-21 | 1997-02-04 | Nisshin Oil Mills Ltd:The | 医療用油脂含有組成物 |
US5952317A (en) * | 1995-09-21 | 1999-09-14 | Wisconsin Alumni Research Foundation | Calcitriol derivatives and their uses |
US5646180A (en) * | 1995-12-05 | 1997-07-08 | Vertex Pharmaceuticals Incorporated | Treatment of the CNS effects of HIV |
US6576636B2 (en) * | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
US5919815A (en) * | 1996-05-22 | 1999-07-06 | Neuromedica, Inc. | Taxane compounds and compositions |
US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
EP0914116B1 (en) * | 1996-05-22 | 2000-10-11 | Protarga Inc. | Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere |
US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
GB9618420D0 (en) * | 1996-09-04 | 1996-10-16 | Scotia Holdings Plc | Fatty acid treatment |
US5976784A (en) | 1996-09-20 | 1999-11-02 | Wisconsin Alumni Research Foundation | Calcitriol derivatives and their uses |
JPH10168047A (ja) | 1996-12-04 | 1998-06-23 | Kao Corp | アミド誘導体及びこれを含有する外用剤組成物 |
US6197764B1 (en) | 1997-11-26 | 2001-03-06 | Protarga, Inc. | Clozapine compositions and uses thereof |
US5955459A (en) * | 1997-11-26 | 1999-09-21 | Neuromedica, Inc. | Fatty acid-antipsychotic compositions and uses thereof |
US6153653A (en) | 1997-11-26 | 2000-11-28 | Protarga, Inc. | Choline compositions and uses thereof |
US5977174A (en) | 1997-11-26 | 1999-11-02 | Neuromedica, Inc. | Cholinergic compositions and uses thereof |
US6225444B1 (en) | 1998-02-10 | 2001-05-01 | Protarga, Inc. | Neuroprotective peptides and uses thereof |
US6184164B1 (en) * | 1999-04-28 | 2001-02-06 | The University Of Houston | Bimodal silicon nitride-bas ceramic composites |
US6459645B2 (en) | 1999-09-30 | 2002-10-01 | Intel Corporation | VPX bank architecture |
-
1996
- 1996-05-22 US US08/651,312 patent/US5795909A/en not_active Expired - Lifetime
-
1997
- 1997-05-22 EP EP97926723A patent/EP0909183B1/en not_active Expired - Lifetime
- 1997-05-22 CA CA002255614A patent/CA2255614C/en not_active Expired - Fee Related
- 1997-05-22 JP JP54281197A patent/JP4402173B2/ja not_active Expired - Fee Related
- 1997-05-22 ES ES97926723T patent/ES2222514T3/es not_active Expired - Lifetime
- 1997-05-22 DE DE69730217T patent/DE69730217T2/de not_active Expired - Lifetime
- 1997-05-22 AU AU31425/97A patent/AU725759B2/en not_active Ceased
- 1997-05-22 WO PCT/US1997/008867 patent/WO1997044063A2/en active IP Right Grant
- 1997-05-22 EP EP04015625A patent/EP1466628A1/en not_active Withdrawn
- 1997-05-22 AT AT97926723T patent/ATE273025T1/de not_active IP Right Cessation
- 1997-05-22 DK DK97926723T patent/DK0909183T3/da active
-
2001
- 2001-05-01 US US09/846,838 patent/US6602902B2/en not_active Expired - Lifetime
-
2003
- 2003-07-14 US US10/618,884 patent/US7199151B2/en not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002512946A (ja) * | 1998-04-23 | 2002-05-08 | オリオン コーポレーション | レボシメンダンの制御放出経口用組成物 |
JP2002538224A (ja) * | 1999-03-09 | 2002-11-12 | プロタルガ,インコーポレーテッド | 脂肪酸−抗癌剤複合体およびこの使用 |
JP2005503423A (ja) * | 2001-09-27 | 2005-02-03 | ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド | コンジュゲートされた抗精神病薬およびこれらの使用 |
JP2007510648A (ja) * | 2003-10-30 | 2007-04-26 | ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク | タキソイド−脂肪酸コンジュゲート及びその医薬組成物 |
JP4884228B2 (ja) * | 2003-10-30 | 2012-02-29 | ザ リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク | タキソイド−脂肪酸コンジュゲート及びその医薬組成物 |
JP2013516486A (ja) * | 2010-01-08 | 2013-05-13 | カタバシス ファーマシューティカルズ,インコーポレイテッド | 脂肪酸フマル酸塩誘導体およびそれらの使用 |
Also Published As
Publication number | Publication date |
---|---|
AU725759B2 (en) | 2000-10-19 |
EP1466628A1 (en) | 2004-10-13 |
ATE273025T1 (de) | 2004-08-15 |
CA2255614C (en) | 2009-12-15 |
US20020010208A1 (en) | 2002-01-24 |
EP0909183B1 (en) | 2004-08-11 |
DE69730217T2 (de) | 2005-07-28 |
JP4402173B2 (ja) | 2010-01-20 |
US5795909A (en) | 1998-08-18 |
DK0909183T3 (da) | 2004-12-20 |
CA2255614A1 (en) | 1997-11-27 |
EP0909183A2 (en) | 1999-04-21 |
WO1997044063A2 (en) | 1997-11-27 |
WO1997044063A3 (en) | 1998-02-26 |
AU3142597A (en) | 1997-12-09 |
DE69730217D1 (de) | 2004-09-16 |
US6602902B2 (en) | 2003-08-05 |
US20040180949A1 (en) | 2004-09-16 |
ES2222514T3 (es) | 2005-02-01 |
US7199151B2 (en) | 2007-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4402173B2 (ja) | Dha―薬剤複合体 | |
US6576636B2 (en) | Method of treating a liver disorder with fatty acid-antiviral agent conjugates | |
US8513304B2 (en) | Topical formulation | |
US8263125B2 (en) | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | |
CN101326275B (zh) | 多功能离子液体组合物 | |
US7976871B2 (en) | Modified release composition of highly soluble drugs | |
US9308181B2 (en) | Topical formulations, systems and methods | |
US20030059471A1 (en) | Oral delivery formulation | |
US20080319092A1 (en) | Transdermal Drug Delivery Formulation | |
US20210322447A1 (en) | Transdermal micro-dosing delivery of psychedelics derivatives | |
US9642912B2 (en) | Topical formulations for treating skin conditions | |
US20230277448A1 (en) | Chewable formulations | |
AU770519B2 (en) | DHA-pharmaceutical agent conjugates | |
CA3208345A1 (en) | Prodrug compositions and methods of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040521 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040521 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20040528 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20040812 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080401 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080624 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080804 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080822 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080929 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081001 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090512 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090812 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090929 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091029 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121106 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121106 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131106 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |